SCM
DBTX

Suvretta Capital Management’s Decibel Therapeutics, Inc. Common Stock DBTX Stock Holding History

Suvretta Capital Management’s Portfolio DBTX Stock Details DBTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-263,600
Closed -$801K – 107
2022
Q1 		$801K Hold
263,600
– – 0.02% 82
2021
Q4 		$1.23M Hold
263,600
– – 0.02% 86
2021
Q3 		$2.03M Hold
263,600
– – 0.03% 93
2021
Q2 		$2.27M Hold
263,600
– – 0.03% 108
2021
Q1 		$2.99M Buy
+263,600
New +$4.14M 0.04% 90

Other funds holding DBTX

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bessemer Group
Bessemer Group Woodbridge, New Jersey $63.6B AUM 28.76% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Suvretta Capital Management's DBTX Position: Q2 2022 in Review

Suvretta Capital Management sold out of Decibel Therapeutics, Inc. Common Stock (DBTX) in Q2 2022, closing a stake of 263,600 shares — an estimated $801K sold.

Suvretta Capital Management first reported a position in DBTX in Q1 2021 and held it in 5 quarters. The position peaked at $2.99M in Q1 2021. 42 funds tracked by Wall St. Rank hold DBTX as of Q2 2022.

  • Suvretta Capital Management reported no remaining Decibel Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Suvretta Capital Management sold 263,600 Decibel Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $801K.
  • Suvretta Capital Management first reported a position in Decibel Therapeutics, Inc. Common Stock in Q1 2021 and held it in 5 quarters.
  • Suvretta Capital Management's Decibel Therapeutics, Inc. Common Stock position peaked at $2.99M in Q1 2021.
  • 42 funds tracked by Wall St. Rank held Decibel Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Suvretta Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.